The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

2010 General Meeting Results

14 Jun 2010 13:38

RNS Number : 5692N
PuriCore Plc
14 June 2010
 



 PuriCore plc 2010 General Meeting Results  

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 14 June 2010 - PuriCore (LSE: PURI), the water-based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, announces that both the Special Resolution and the Ordinary Resolution were duly passed at its General Meeting held earlier today. Proxy figures will be displayed shortly on the Company's investor website at http://investor.puricore.com.

 

Copies of the resolutions have been filed with the United Kingdom Listing Authority's Document Viewing Facility and are available for inspection at:

 

The Financial Services Authority

UKLA Document Viewing Facility

25 The North Colonnade

Canary Wharf

London

E14 5HS

 

 

Enquiries:

Ben Brewerton

Susan Quigley

Financial Dynamics

+44 (0) 20 7831 3113

Greg Bosch, CEO

Darren Weiss, CFO

PuriCore

+1 484 321 2700

 

 

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.

 

 

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGFIMTTMBJBBTM

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.